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sthma affects millions of people worldwide, and its re- 
ported  incidence  is  increasing  dramatically  in  many 
developed nations;  the human and economic costs  of this 
disorder,  in morbidity, health care expenses, lost productivity, 
and, most tragically, even mortality, are staggering (1, 2). 
It is now generally thought that asthma is a syndrome, 
typically characterized by the three cardinal features of in- 
termittent and reversible airway obstruction, airway hyper- 
responsiveness,  and airway inflammation,  that may arise 
as  a result of interactions between multiple genetic and en- 
vironmental factors (1-4).  Nevertheless, most cases of the 
disorder (the so-called "atopic" or "allergic" asthma) occur 
in  subjects whom  also  exhibit immediate hypersensitivity 
responses to defined environmental allergens, and challenge 
of the airways of these subjects with such allergens can pro- 
duce reversible airway obstruction (1-5). It is also known 
that the overall incidence of asthma  in several different pop- 
ulations  exhibits  a  strong positive correlation with  serum 
concentrations of IgE, which, in humans, is the main (if not 
the only) Ig isotype that can mediate immediate hypersen- 
sitivity  responses  (1,  5).  Moreover,  it  has  been  demon- 
strated that mast cells, derivatives of hematopoietic precursor 
cells  that undergo their terminal stages  of differentiation/ 
maturation in the peripheral tissues in which they reside (6, 
7), express cell surface receptors (Fcd~I) that permit them 
to bind the Fc portion of IgE with high affinity, and also 
that  such  lgE-sensitized mast  cells,  upon  encounter with 
specific antigen that  is  recognized by their FcdkI-bound 
IgE, secrete a broad panel of bioactive mediators, includ- 
ing: (a) preformed mediators that are stored in the cell's cy- 
toplasmic  granules  (e.g.,  histamine,  heparin,  and  neutral 
proteases),  (b) newly synthesized lipid products (e.g., prosta- 
glandin D 2 and leukotriene C4),  and  (c)  diverse cytokines 
(4,  6,  8,  9).  Finally, several lines of evidence indicate that 
many of these potentially mast cell-derived mediators can 
promote reversible airway obstruction, bronchial hyperre- 
activity, and/or airway inflammation (see reviews in refer- 
ences 2-4, 8, and 9). 
In  light  of these findings,  it was  once widely believed 
that atopic or allergic asthma is a disease  that primarily re- 
flects  the  consequences  of IgE-  and  allergen-dependent 
mast  cell activation.  Yet  several observations  have  called 
into question the central role of mast cells in asthma. These 
include  the  demonstration  that  additional  cell  types,  in- 
cluding eosinophils  (10)  and Th2 lymphocytes (11),  both 
of which are well represented in the chronic inflammatory 
infiltrates in the airways of patients with asthma  (2-4,  12, 
13), also can produce cytokines or other mediators that may 
contribute to many of the features of the  disease.  More- 
over, it has recently been shown that the Fcd<I, which was 
once thought to be restricted to tissue mast cells and baso- 
phils  (circulating granulocytes that can produce a panel of 
mediators that is similar,  but not identical, to that of mast 
cells [6, 9]) can also be expressed on the surface of mono- 
cytes, circulating dendritic cells, Langerhans' cells, and eo- 
sinophils (see reviewes in references 14 and 15), thus iden- 
tifying these cells as additional potential sources  of mediators 
in various IgE-dependent inflammatory responses. 
Given the  large  number of potential  culprits,  some  of 
which  can  express similar  or overlapping functions,  how 
can  one  assess the  relative  importance  of individual  cell 
types in the pathogenesis of asthma? Although this repre- 
sents an exceedingly difficult challenge in the setting of hu- 
man asthma, some aspects of this issue are accessible by tak- 
ing advantage of animal models of the disease.  However, 
when considering the results of such animal studies, several 
points should be kept in mind. (a) These are models of hu- 
man asthma, not asthma itself, and the extent to which the 
findings in these models actually elucidate the human con- 
dition(s) needs to be demonstrated by appropriate studies in 
human  subjects.  (b)  Experimental animal  species and hu- 
mans can differ in significant details  of immunological and 
inflammatory responses  (e.g.,  in  the mouse,  antigen-  and 
mast  cell-dependent airway obstruction can be  mediated 
by either IgE or IgG1 [16], whereas it seems hkely that only 
IgE is involved in the analogous human responses [1,  5]). 
(c) The procedures of allergen sensitization and  challenge 
that are used in animal models of asthma are typically "op- 
timized" to give strong responses for endpoint analysis, and 
this (as well as the increasing costs of animal experimenta- 
tion, which discourages the  use of large numbers  of ani- 
mals)  may make it difficult to detect contributions of cell 
types that function to amphfy the intensity or kinetics of 
such responses at relatively low levels of allergen challenge. 
(d) Finally, the models used by different investigators may 
differ in  a number of factors, which can have potentially 
significant effects on the results,  including the  species  (or 
strain)  of experimental animal,  the  choice of antigen,  the 
protocols for antigen sensitization and challenge,  and  the 
means of assessing and quantifying the individual character- 
istics of the responses. 
In other words, the demonstration that a particular cell 
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model neither proves that this element can have the same 
effect in  human  asthma  nor  excludes the  possibility that 
other cells or mediators can have similar,  and perhaps even 
more critical, functions, either in experimental animals or 
humans. 
These reservations notwithstanding, how have the results 
of studies in experimental animals influenced our thinking 
about the pathogenesis of asthma, and in particular, the po- 
tential role of the mast cell in the expression of the three 
cardinal features of the  disorder? The most definitive ap- 
proach for characterizing the importance of a single poten- 
tial effector cell or molecule in a biological response is to 
attempt to elicit the response in animals that differ solely in 
having or lacking the element of interest. With respect to 
mast cells, the best current approximation of this ideal is to 
investigate  genetically  mast  cell-deficient  (WB-W/+  × 
C57BL/6- Wv/+) F 1- W~ 18/v (WBB6F  1- W~ Ill  Iv)  mice  (now 
more properly designated WBB6F1-KitW/Kit w-v mice [17]) 
and  the  congenic  normal  (WBB6FI-+/+)  mice  (6,  18, 
19). Because of the effects of  their mutations at c-kit, which 
encodes the  receptor for a pleiotropic growth factor that 
represents a major mast cell survival/developmental factor, 
stem  cell  factor  (also  known  as  kit  ligand  or  mast  cell 
growth  factor;  18),  adult  KitW/Kit w-v  mice  virtually lack 
tissue mast cells (<1.0% the  +/+  number in the skin, es- 
sentially none in the airways and other sites), but they are 
also mildly anemic, lack melanocytes in the skin and inter- 
stitial  cells  of Cahal  in  the  gastrointestinal  tract,  and  are 
sterile due to a virtual absence of germ cells (18-22). How- 
ever, these mice appear to have little or no abnormalities of 
B or T  cell function, levels of granulocytes (including baso- 
phils) or platelets,  or hemostasis,  nor do they exhibit Ig defi- 
ciencies or impairments in their ability to generate IgE or 
IgG1 antibody responses (18,  19). Finally, the mast cell de- 
ficiency of KitW/Kit w-v mice can be selectively repaired by 
the adoptive transfer of lineage-committed immature mast 
cells  (BMCMCs,  or bone  marrow-derived cultured mast 
cells)  which have been generated in vitro from the bone 
marrow cells of the congenic +/+  mice (6,  19, 21). Such 
"mast cell knock-in mice" can be used to test whether ab- 
normalities  in  the  expression  of biological  responses  in 
KitW/Kit w-v mice, which theoretically could be due to any 
direct  or  indirect  consequence  of their  c-kit  mutations, 
specifically reflect the animals'  mast cell deficiency (6,  18, 
19, 21). 
Studies in KitW/Kit w-~ and congenic normal mice have 
clearly established  that,  in  the  mouse:  (a)  IgE-dependent 
acute  reversible airway obstruction can occur by mecha- 
nisms  that appear to be entirely mast cell dependent  (16, 
22,  23).  (b)  Although  many manifestations of active ana- 
phylactic reactions in the mouse, including changes in air- 
way function and death, can occur by IgE- and mast cell- 
independent,  but  IgGl-dependent,  mechanisms,  IgE  and 
mast  cells  probably  contribute  importantly  to  the  initial 
rapid and partially reversible phases of airway obstruction, 
and diminished pulmonary compliance, that are observed 
during certain models  of active anaphylaxis  (16).  (c)  The 
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acute  airway  hyperresponsiveness  to  intravenous  metha- 
chohne challenge that can be detected in immunologically 
naive mice 20 min after intravenous challenge with anti- 
mouse  IgE  antibodies is largely (if not entirely) mast cell 
dependent, and is expressed before the development of any 
histologically apparent leukocyte infi trafion in the airways at 
sites of mast cell degranulation (23).  Although the specific 
mediator(s)  responsible  for this  example of mast cell-depen- 
dent airway hyperreactivity remain to be defined, the can- 
didates  include representatives of all  three  classes of mast 
cell-derived mediators  (see  reviews in references 4,  8,  9, 
and 23). 
These findings show that, in WBB6F1 mice, IgE-depen- 
dent mast  cell degranulation can result in both reversible 
airway obstruction and airway hyperresponsiveness to cho- 
linergic stimulation, in the absence of detectable infiltration 
of the  airways with  circulating leukocytes. On  the  other 
hand, it is now clear that eosinophil recruitment to the air- 
ways  of mice  can  occur in  response to  aerosol challenge 
with antigen even in the virtual absence of mast cells,  at 
least with some protocols of antigen sensitization and chal- 
lenge. For example, in this issue,  Takeda et al.  (24) report 
that when KitW/Kit w-~ and congenic +/+  mice were sen- 
sitized with OVA and then assessed 48 h after the last of 3 
consecutive daily aerosol challenges with OVA,  both the 
mast cell-deficient and the wild type mice exhibited similar 
numbers of eosinophils in bronchoalveolar lavage fluid and 
lung digests, as well as similar levels of airway hyperreactiv- 
ity to methachohne challenge. 
At least four previous studies (each using a different pro- 
tocol of antigen sensitization and challenge, and,  in some 
cases,  a different antigen)  also  reported that mast cells are 
not essential  for the development of antigen-induced infil- 
tration of the airways with eosinophils (25-28). However, 
Kung et al.  (27),  using a protocol in which aerosol chal- 
lenge with OVA was performed only twice on a single day, 
found that eosinophil infiltration of the  airways in  KitW/ 
Kit  w-v mice was ~<50% of that in the +/+  mice (P <0.05) 
and was largely normalized after the selective repair of the 
animals' mast cell deficiency. Brusselle et al. (26), who per- 
formed daily OVA challenge for 7 d, also found that eosin- 
ophil influx into bronchoalveolar lavage fluid was reduced 
by N50% in KitW/Kit w-v versus +/+  mice (P =  0.06). 
Taken together, these five studies suggest that the rela- 
tive contribution of mast cells to eosinophil infiltration of 
the  airways may vary; mast  cells  may have no  detectable 
role in experiments that use strong procedures of immuni- 
zation and challenge, but may contribute significandy when 
protocols for sensitization  and,  especially,  challenge have 
been selected to yield relatively attenuated responses.  More- 
over, in a model of peritoneal inflammation, the mast cell 
significantly  enhanced  the  kinetics  of leukocyte  recruit- 
ment, even though it had no effect on the final magnitude 
of the response (29).  The data of Kung et al.  (27) indicate 
that mast cells can also  enhance the kinetics of eosinophil 
responses to aerosol allergen challenge. 
Takeda et al.  (24)  are the first to show that mast cell- 
deficient  KitW/Kit  w-~  mice  can  express  allergen-induced airway hyperresponsiveness to cholinergic stimulation. This 
important  observation provides yet more support for the 
now widespread view that there may be multiple routes to 
this defining characteristic of asthma.  Indeed, it is thought 
that airway hyperresponsiveness, i.e.,  the  development of 
bronchoconstriction  in  response  to  an  immunologicaUy 
nonspecific stimulus that would have no discernable effect 
in a normal individual, may reflect a consequence of any of 
a  number  of acute  and/or  chronic  processes,  including 
damage to the bronchial epithelium, submucosal edema, al- 
terations of smooth muscle function (e.g.,  in response to 
mast cell mediators or other products present at sites of in- 
flammation), and alterations in the production or degrada- 
tion of neuroactive mediators (4, 8, 30). And although air- 
way  hyperresponsiveness  and  infiltration  of the  airways 
with  eosinophils are  often linked,  both in animal models 
and in human asthma, airway hyperresponsiveness has been 
reported to occur in the absence of significant eosinophilia 
in  certain  settings  such  as  in  aerosol-challenged BALB/c 
mice that had been treated with an anti-IL-5 neutralizing 
antibody (31). 
Depending on the  model system,  airway hyperrespon- 
siveness  also  can  occur either by IgE-dependent  mecha- 
nisms  (23,  32)  or independently of IgE  (33,  34)  and/or 
IgG1 (34). IL-5 derived from CD4 + T  cells has been impli- 
cated in the development of IL-4- and IgE/IgGl-indepen- 
dent airway inflammation (34),  adding to a large body of 
evidence that indicates that CD4 + T  cells can mediate air- 
way hyperreactivity (35-37)  as  well as  infiltration of the 
airways with eosinophils (25,  35-38). And although it has 
often been proposed that CD4 + T  cells promote the devel- 
opment of airway hyperreactivity indirectly through the re- 
cruitment of eosinophils and/or other teukocytes, the pos- 
sibility that products derived from the  T  cells  themselves 
can importantly contribute to airway hyperresponsiveness 
must also be considered (35). 
Perhaps the simplest conclusions to draw from the vari- 
ous studies of mouse models of allergic asthma are that, in 
mice: (a) Airway hyperreactivity to cholinergic stimulation 
can occur by either mast cell-dependent mechanisms (which 
can be expressed even in the absence of leukocyte recruit- 
ment) or by CD4 + T  cell-dependent mechanisms  (which 
typically occur in a setting that also includes eosinophil infil- 
tration of the airways).  (b) Mast cells are not necessary for 
the recruitment of Th2 cells or eosinophils to the airways af- 
ter aerosol challenge with antigen, but can influence the 
kinetics or magnitude of the responses, especially at "sub- 
optimal" levels of antigen exposure. (c) The extent to which 
eosinophils  are  necessary  for  the  expression  of T  cell- 
dependent changes in airway hyperreactivity  in different mod- 
els remains to be fully defined.  (d)  In many experimental 
settings, particularly in various strains  of normal mice, the 
expression of  airway hyperresponsiveness  (and other "asthma- 
like" features of these models) probably reflects the com- 
bined contributions of both mast cell- and T  cell-depen- 
dent pathways. 
But what about the role of the mast cell in "real" allergic 
asthma, in humans? It seems very likely that IgE-dependent 
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mast cell activation importantly contributes to acute aller- 
gen-induced bronchoconstriction in human atopic asthma, 
and that mast cells can contribute to the airway inflamma- 
tion  associated  with  this  disorder  as  well  (2-4,  6,  8,  9). 
However, in humans, unlike in mice, the FceRI can be ex- 
pressed on several potential effector cells in addition to mast 
cells  and basophils  (14,  15).  Also,  the form of the  FceP,.I 
expressed on monocytes and dendritic cells (which lacks the 
[3 chain) can function to enhance the processing/presenta- 
tion of antigens attached to proteins that are recognized by 
the cells' surface-bound IgE (14). Thus, in humans, IgE may 
not only serve to arm mast cells and other effectors of the 
efferent limb of acquired immune responses, but may also 
contribute, by promoting antigen processing/presentation, 
to the evolution of such responses. 
In  addition,  two  newly  recognized  aspects  of FceRI 
function or expression provide strong support for the hy- 
pothesis that mast cells (and perhaps other FceR.I  + effector 
cells)  may have  a particularly important role in initiating 
and/or amplifying IgE-dependent inflammatory reactions, 
especially in response tolow dose antigen challenge. First, 
Linet al. (39) have identified the FceRI [3 chain as an "am- 
plifier" of  signaling through this receptor, which can mark- 
edly upregulate the magnitude of the mediator release re- 
sponse to FceR.I aggregation; notably, it has been reported 
that certain mutations that result in amino acid substitutions 
in the human [3 chain may be linked to atopic disease  (see 
reviews in reference 39). Second, studies in both mice (40, 
41) and humans  (42,  43) indicate that the level of expres- 
sion of FceI(I on the surface of  mast cells and basophils can 
be regulated by ambient concentrations of IgE and that this 
IgE-dependent upregulation of FceI(I expression both per- 
mits the cells to exhibit mediator release at lower concen- 
trations  of specific antigen  (40,  42,  43),  and  also  primes 
such cells to produce strikingly higher levels of certain me- 
diators, including IL-4 and other cytokines (40,  43), under 
optimal conditions of antigen challenge. 
These  findings  thus  identify  two  Fc~RI-dependent 
mechanisms ([3 chain "amplifier" function, IgE-dependent 
upregulation of FceRI surface expression)  for enhancing the 
sensitivity and intensity of  the effector  phase of IgE-dependent 
reactions.  They also  suggest  a  potential positive feedback 
mechanism (q'IgE---)'['Fcel~I--)$antigen-,  IgE-, and FceRI- 
dependent release of IL-4 [40]  and/or IL-13  [44]--)~'IgE) 
by which mast cells  (and possibly basophils)  may enhance 
the further evolution, and persistence, of Th2-biased, IgE- 
associated  immune  responses.  And  studies  in  mice  have 
identified yet another IgE-dependent, but apparently mast 
cell- and FceP,  J-independent, mechanism to augment Th2 
responses and associated eosinophil infiltration in the  air- 
ways: IgE- and CD23-facilitated antigen presentation to T 
cells (28). Finally, mast cells and basophils may enhance IgE 
production via expression of the CD40 ligand (44, 45). 
The clinical significance of these new findings largely re- 
mains  to be established.  However, this work clearly sup- 
ports a complex, but more unified, view of the pathogene- 
sis of allergic diseases, which proposes that both T  cells and 
mast cells  (and other FceRI + cells) can have both effector cell and immunoregulatory roles in these disorders.  This hy- 
pothesis has a  number of interesting  implications  with re- 
spect to existing,  and proposed, therapeutic  approaches for 
asthma and other allergic  diseases.  For example,  anti-IgE- 
based  strategies,  which  are  already in clinical  testing  (42), 
not  only may reduce  CD23-dependent  antigen  presenta- 
tion  (28)  and  FceRI  +  cell  effector function  (40-43),  but 
also may diminish FceRI  + cell immunoregulatory function by 
reducing both mast cell  (or basophil)  IL-4/IL-13 produc- 
tion  (40,  44)  and  Fc~Rl+-dependent  antigen presentation 
(14). Conversely, the findings that corticosteroids and other 
"immunosuppressive"  drugs  can  diminish  mast  cell  cyto- 
kine  production,  as  well  as  reduce  IgE-  and  mast  cell- 
dependent inflammation and leukocyte recruitment in mice 
in vivo (see reviews in references 9, and 46), raise the possi- 
bility that the clinical benefits of such agents in asthma may 
reflect, at least in part, actions on mast cells as well as on the 
T  cells,  eosinophils,  and other effector and target cells  that 
participate in these complex disorders. 
Address correspondence  to Stephen J.  Galli, Division  of Experimental  Pathology, Beth Israel Deaconess 
Medical Center-East Campus,  330 Brookline Ave., Boston, MA 02215. Phone: 617-667-5970; FAX: 617- 
667-3616;  E-mail: sgalli@bidmc.harvard.edu 
Received  for publication  29 May  1997 and in revised  form  11June 1997. 
References 
1. Evans, R., Ill. 1993. Epidemiology and natural history of  asthma, 
allergic  rhinitis,  and atopic dermatitis.  In Allergy.  Principles 
and Practice.  Vol.  I. 4th ed.  E. Middleton, Jr.,  C.E.  Reed, 
E.F.  EUis, N.F.  Adkinson, Jr., J.W.  Yuninger,  and  W.W. 
Busse, editors. Mosby--Year Book, Inc., St. Louis. 1109-1136. 
2.  Goldstein, R.A., W.E. Paul, D.D. Metcalfe, W.W. Busse, and 
E.R. Reece. 1994. Asthma.  Ann. Intern. Med. 121:698-708. 
3.  Pare, P.D., and T.R. Bai. 1995. The consequences of chronic 
aller~c  inflammation.  Thorax. 50:328-332. 
4.  Drazen, J.M., J.p. Arm, and K.F.  Austen.  1996.  Sorting out 
the cytokines in asthma.J. Exp. Med.  183:1-5. 
5.  Ownby, D.R.  1993.  Clinical  significance  of IgE. In Allergy. 
Principles  and Practice.  Vol. I. 4th ed. E. Middleton, Jr., C.E. 
Reed,  E.F.  Ellis, N.F.  Adkinson, Jr., J.W.  Yuninger,  and 
W.W.  Busse,  editors.  Mosby--Year Book,  Inc.,  St.  Louis. 
1059-1076. 
6.  Galli, S.J. 1993. New concepts about the mast cell. N. EngI.J. 
Med. 328:257-265. 
7.  Rodewald, H.-R., M. Dessing,  A.M. Dvorak, and S.J. Galli. 
1996.  Identification of a committed precursor for the mast 
cell lineage.  Science (Wash. DC). 271:818-822. 
8.  Holgate, S.T., C. Robinson, and M.K. Church. 1993. Medi- 
ators of immediate hypersensitivity.  In Allergy. Principles  and 
Practice.  Vol.  I. 4th ed. E. Middleton, Jr.,  C.E. Reed, E.F. 
Ellis, N.F.  Adkinson, Jr., J.W.  Yuninger,  and W.W. Busse, 
editors.  Mosby--Year Book, Inc., St. Louis. 267-301. 
9.  Galli, S.J., and J.J.  Costa.  1995. Mast cell leukocyte cytokine 
cascades in allergic inflammation. Allergy (Cph.). 50:851-862. 
10. Weller,  P.F.  1991.  The  immunobiology of eosinophils.  N. 
Engl.J. Med. 324:1110-1118. 
11. Mosmann, T.R., and R.L. Coffman. 1989. Heterogeneity of 
cytokine secretion patterns  and functions of helper T  cells. 
Adv. Immunol. 46:111-147. 
12. Bousquet, J., p. Chanez, J.Y. Lacoste,  G. Barneon, N. Gha- 
vanian, I. Enander, P. Venge, S. Ahlstedt, J. Simony-Lafon- 
taine,  and  P.  Godard.  1990.  Eosinophilic  inflammation  in 
asthma. N. Engl.J.  Med. 323:1033-1039. 
13. Robinson, D.S., Q. Hamid, S. Ying, A. Tsicopoulos, J. Bar- 
kans,  A.M.  Bentley,  C.  Corrigan,  S.R.  Durham,  and A.B. 
Kay.  1992.  Predominant  TH2-1ike  bronchoalveolar T-lym- 
phocyte population in atopic asthma.  N.  Engl. J.  Med.  326: 
298-304. 
14. Maurer, D., E. Fiebiger,  C. Ebner, B. Reininger, G.F. Fisher, 
S. Wichlas, M.-H. Jouvin, M. Schmitt-Egeno~,, D. Kraft, J.-P. 
Kinet,  and G.  Stingl.  1996.  Peripheral blood dendritic  cells 
express  FceRI  as  a  complex  composed  of FceRI0t-  and 
FceRb/-chains and can use this receptor for IgE-mediated al- 
lergen presentation.J.  Immunol. 157:607-616. 
15. Gounni, A.S., B. Lamkhioued, K. Ochiai, Y. Tanaka, E. De- 
laporte,  A. Capron, J.-P. Kinet, and M. Capron. 1994. High- 
aflfinity IgE receptor  on eosinophils  is  involved in  defense 
against parasites. Nature (Lond.). 367:183-186. 
16. Miyajima I., D. Dombrowicz, T.R. Martin, J.V. Ravetch, J.-P. 
Kinet,  and  S.J. Galli.  1997.  Systemic  anaphylaxis  in  the 
mouse can be mediated largely  through IgG1 and Fc~/RIII. 
Assessment  of the  cardiopulmonary  changes,  mast  cell  de- 
granulation,  and death associated with active or IgGl-depen- 
dent passive anaphylaxis. J.  Clin. Invest. 99:901-914. 
17. Witham, B.A. 1995. Nomenclature update: symbols affecting 
mutant genes.JAX Notes. No. 461.  The Jackson Laboratory, 
Bar Harbor, ME. 
18. Galli,  S.J., K.M.  Zsebo,  and E.N.  Geissler. 1994.  The  kit 
ligand, stem cell factor. Adv. Immunol. 55:1-96. 
19. Galli,  S.J., and Y. Kitamura.  1987.  Animal model of human 
disease.  Genetically  mast  cell-deficient  W/lJ/v  and  SI/SI  ~ 
mice: their value  for the analysis of the roles of mast cells in 
biological responses in vivo. Am.J. Pathol. 127:191-198. 
20. Maeda,  H.,  A.  Yamagata,  S.  Nishikawa,  K.  Yoshinaga,  S. 
Kobayashi, K. Nishi, and S.I. Nishikawa. 1992. Requirement 
of c-kit for development of intestinal  pacemaker system. De- 
velopment (Camb.). 116:369-375. 
21.  Nakano,  T.,  T.  Sonada,  C.  Hayashi,  A.  Yamatodani,  Y. 
Kanayama, T. Yamamura, H. Asai, Y. Yonezawa, Y.  Kita- 
mura, and S.J. Galli. 1985. Fate of bone marrow-derived cul- 
tured mast  cells after  intracutaneous,  intraperitoneal  and in- 
travenous transfer into genetically  mast cell-deficient  W~ W v 
mice. Evidence that cultured mast cells can give rise to both 
connective tissue-type  and mucosal mast cells. J.  Exp.  Med. 
162:1025-1043. 
22. Takeishi,  T., T.R. Martin, I.M. Katona, F.D. Finkelman, and 
S.J. Galli.  1991.  Differences  in the expression  of the cardio- 
pulmonary alterations  associated  with  anti-immunoglobulin 
E-induced  or active  anaphylaxis  in  mast  cell-deficient  and 
normal mice. Mast cells are not required for the cardiopul- 
346  Commentary monary changes associated with certain fatal anaphylactic re- 
sponses.J. Clin.  Invest. 88:598-608. 
23. Martin,  T.R.,  T.  Takeishi,  H.R.  Katz,  K.F.  Austen, J.M. 
Drazen,  and S.J. Galli.  1993.  Mast cell activation enhances 
airway responsiveness to methacholine in the mouse. J.  Clin. 
Invest. 91:1176-1182. 
24. Takeda,  K.,  E.  Hamelmann,  A. Joetham,  L.  Shultz,  G.L. 
Larsen, C.G. Irvin, and E.W. Gelfand. Development ofeosin- 
ophilic airway inflammation and airway hyperresponsiveness 
in mast cell-deficient mice.J. Exp. Med.  186:449-454. 
25. Nogami, M., M. Suko, H. Okidaira, T. Miyamoto, J. Shiga, 
M. Ito, and S. Kasuya. 1990. Experimental pulmonary eosin- 
ophilia in mice by Ascaris suum extract. Am.  Rev. Respir. Dis. 
141:1289-1295. 
26. Brusselle, G.G., J.C. Kips, J.H. Tavernier, J.G. Van Der Hey- 
den,  C.A.  Cavelier,  R.A.  Pauwels,  and  H.  Bluethmann. 
1994. Attenuation of allergic airway inflammation in IL-4 de- 
ficient mice. Clin.  Exp. Allergy.  24:73-80. 
27. Kung, T.T., D. Stelts, J.A. Zurcher, H. Jones, S.P. Umland, 
W. Kreumer, R.W. Egan, and R.W. Chapman.  1995.  Mast 
cells modulate allergic pulmonary eosinophilia in mice. Am. 
J. Respir.  Cell Mol. Biol.  12:404-409. 
28. Coyle, A.J., K. Wagner, C. Betrand, S. Tsuyuki, J. Bews, and 
C. Heusser.  1996.  Central role of immunoglobulin (Ig) E in 
the induction of lung eosinophil infiltration and T  helper 2 
cell cytokine production: inhibition by a non anaphylactoge- 
nic anti-IgE antibody.J. Exp. Med.  183:1303-1310. 
29. Qureshi, R., and B.A. Jakschik. 1988.  The role of mast cells 
in  thioglycollate-induced inflammation. J.  Immunol.  145: 
2090-2096. 
30. O'Byme,  P.M.  1993.  Airway hyperresponsiveness.  In  Al- 
lergy. Principles and Practice. Vol. I. 4th ed. E. Middleton, 
Jr., C.E. Reed, E.F. Ellis, N.F. Adkinson, Jr., J.W. Yuninger, 
and  W.W.  Busse.  editors.  M0sby--Year  Book,  Inc.,  St. 
Louis. 1203-1213. 
31. Corry,  D.B.,  H.G.  Folkesson,  M.L.  Wamock,  D.J.  Erle, 
M.A. Matthay, J.p. Wiener-Kronish, and R.C. Locksley. 1995. 
Interleukin 4, but not interleukin 5 or eosinophils, is required 
in  murine  model  of acute  airway hyperreactivity. J.  Exp. 
Med.  183:109-117. 
32.  Hamelmann,  E.,  A.T.  Vella,  A.  Oshiba, J.W.  Kappler,  P. 
Marrack, and E.W. Gelfand. 1997.  Allergic airway sensitiza- 
tion induces T  cell activation but not airway hyperrespon- 
siveness  in B  cell-deficient mice. Proc. Natl. Acad.  Sci. USA. 
94:1350-1355. 
33. Mehlhop, P.D., M. van de Rijn, A.B. Goldberg, J.P. Brewer, 
V.P.  Kurup,  T.R.  Martin, and H.C.  Oettgen.  1997.  Aller- 
gen-induced bronchial hyperreactivity and  eosinophilic in- 
flammation occur in the absence of IgE in a mouse model of 
asthma. Proc. Natl. Acad.  Sci. USA. 94:1344-1349. 
34. Hogan, S.P., A. Mould, H. Kikutani, AJ. Ramsay, and P.S. 
Foster.  1997.  Aeroallergen-induced eosinophilic inflamma- 
tion, lung damage, and airways hyperreactivity in mice can 
occur independently of IL-4 and allergen-specific immuno- 
globulins.J. Clin.  Invest. 99:1329-1339. 
35. Garssen, J.,  F.P.  Nijkamp, H.  Van  Der Vliet,  and  H.  Van 
Loveren. 1991.  T-cell-mediated induction of airway hyper- 
reactivity in mice. Am. Rev. Respir. Dis. 144:931-938. 
36. Gavett, S.H.,  X.  Chen,  F.  Finkelman, and M.  Wllls-Karp. 
1994.  Depletion of murine  CD4 +  T  lymphocytes prevents 
antigen-induced airway hyperreactivity and pulmonary eosin- 
ophilia. Am.J. Respir.  Cell Mol. Biol.  10:587-593. 
37. Watanabe, A., H.  Mishima, P.M. Renzi,  L.-J. Xu,  Q.  Ha- 
mid, and J.G.  Martin.  1995.  Transfer of allergic airway re- 
sponses with antigen-primed CD4+  but not CD8+  T  cells 
in Brown Norway rats.J. Clin. Invest. 96:1303-1310. 
38. Korsgren,  M., J.S.  Erjefalt,  O.  Korsgren,  F.  Sundler,  and 
C.G.A. Persson. 1997.  Allergic eosinophil-rich inflammation 
develops in  lungs  and  airways of B  cell-deficient mice. J. 
Exp. Med.  185:885-892. 
39. Lin, S., C. Ciccala, A.M. Scharenberg, andJ.-P. Kinet. 1996. 
The  FceRI~ subunit functions as an amplifier of Fc~RI~- 
mediated cell activation signals. Cell. 85:985-995. 
40. Yamaguchi, M., C.S. Lantz, H.C.  Oettgen, I.M. Katona, T. 
Fleming, I. Miyajima, J.-P.  Kinet, and S.J.  GaUL 1997.  IgE 
enhances mouse mast cell FceRI expression in vitro and in 
vivo. Evidence for a novel amplification mechanism in IgE- 
dependent reactions.J. Exp. Med.  185:663-672. 
41. Lantz, C.S., M.  Yamagnchi, H.C.  Oettgen,  I.M. Katona, I. 
Miyajima,  J.-P. Kinet, and S.J. Galli. IgE regulates mouse ba- 
sophil FceRI expression in vivo.J. Immunol.  158:2517-2521. 
42. MacGlashan, D.W., Jr., B.S. Bochner, D.C. Adelman, P.M. 
Jardieu,  A.  Togias,  J.  McKenzie-White,  S.A.  Sterbinsky, 
R.G. Hamilton, and L.M. Lichtenstein. 1997.  Down-regula- 
tion of Fc{RI expression on human basophils during in vivo 
treatment of atopic patients with anti-IgE antibody.  J. Immu- 
nol. 158:1438-1445. 
43. Yano, K., M. Yamagnchi, F. de Mora, C.S. Lantz, J.H. But- 
terfield, JJ.  Costa, and S.J. Galli. 1997.  Production of mac- 
rophage inflammatory protein-let by human mast cells.  In- 
creased  anti-IgE-dependent  secretion  after  IgE-dependent 
enhancement of mast cell IgE binding ability. Lab.  Invest.  In 
press. 
44. Pawankar,  R.,  M.  Okuda,  H.  Yssel,  K.  Okumura,  and  C. 
Ra.  1997.  Nasal mast cells in perennial allergic rhinitic ex- 
hibit increased expression of the FceRI, CD40L,  IL-4, and 
IL-13, and can induce IgE synthesis in B cells.J. Clin.  Invest. 
99:1492-1499. 
45. Gauchet, J.F., S. Henchoz, G. Mazzei, J.p. Aubry, T. Brun- 
ner,  H.  Blasey,  P.  Life,  T.  Talabot,  L.  Flores-Romo, J. 
Thompson, et al.  1993.  Induction of human IgE synthesis in 
B cells by mast cells and basophils. Nature (Lond.). 365:340-343. 
46. Wershil, B.K., G.T. Fumta, J.A. Lavigne, A. Roy Choudhury, 
Z.-S.  Wang,  and  SJ.  Galli.  1995.  Dexamethasone  or  cy- 
closporin A  suppress mast cell-leukocyte cytokine cascades. 
Multiple mechanisms  of inhibition of IgE- and  mast  cell- 
dependent cutaneous inflammation in the mouse. J. Immunol. 
154:1391-1398. 
347  Galli 